Patent: 6,709,655

« Back to Dashboard

Summary for Patent: 6,709,655

Title:	Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
Abstract:	The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab′)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized, as a source of antibodies. The serum or blood plasma is digested with pepsin, followed by separation and purification until the pharmaceutical composition of F(ab′)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.
Inventor(s):	Juan López de Silanes, Rita Mancilla Nava, Jorge F. Paniagua Solis
Assignee:	Instituto Bioclon de C V SA
Application Number:	US09/798,076
Patent Claims:	see list of patent claims

What does US Patent 6,709,655 actually claim, and how crowded is the US patent landscape?

No usable claim text was provided. Without the full claim set (or at least independent claims and claim numbering), a complete and accurate claim-by-claim analysis and landscape mapping for US Patent 6,709,655 cannot be produced.

Can a full claims-and-landscape analysis be completed without the claims text?

No.

What does that mean for the patent landscape review?

A landscape review requires the claim scope (independent claim elements, dependencies, and claim terms) to identify:

• The literal claim boundaries in US filings
• The relevant prior art classes and claim analogs
• The likely claim-construction outcomes that determine freedom-to-operate and invalidity risk

Without the claims, there is no reliable basis to map the landscape or assess novelty, non-obviousness, or enforceability.

Key Takeaways

• A comprehensive, critical analysis of US Patent 6,709,655 requires the complete claim text.
• Patent-landscape conclusions depend on independent-claim elements and claim dependencies; those were not provided.

FAQs

1. What is required to analyze US Patent 6,709,655 claims critically?
   The full claim set, at minimum the independent claims with exact wording and claim dependencies.

2. Why can’t the patent landscape be evaluated without claim scope?
   Landscape mapping targets claim elements, not the patent title or general subject matter.

3. What parts of the claims drive landscape and validity risk most?
   Claim terms that define structure, composition, process steps, and functional limitations; plus dependent claim narrowers that establish what is actually protected.

4. How does missing claim text change an invalidity assessment?
   It prevents a correct element-by-element prior art comparison and blocks a proper anticipation/obviousness analysis.

5. Can a landscape review be done using only the patent number?
   Not to the standard implied here, because claim wording determines which citing and competing applications are actually relevant.

References

[1] No sources cited because US Patent 6,709,655 claim text was not provided in the prompt.

Details for Patent 6,709,655

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc		antivenin (latrodectus mactans)	For Injection	101062	February 13, 1936	6,709,655	2021-02-28
Rare Disease Therapeutics, Inc. (rdt)	ANASCORP	centruroides (scorpion) immune f(ab')2 (equine) injection	For Injection	125335	August 3, 2011	6,709,655	2021-02-28
Rare Disease Therapeutics, Inc. (rdt)	ANAVIP	crotalidae immune f(ab')2 (equine)	For Injection	125488	May 6, 2015	6,709,655	2021-02-28